| Literature DB >> 25524210 |
Susan Reif1, Brian Wells Pence, Irene Hall, Xiaohong Hu, Kathryn Whetten, Elena Wilson.
Abstract
A group of nine states in the Southern United States, hereafter referred to as the targeted states, has experienced particularly high HIV diagnosis and case fatality rates. To provide additional information about the HIV burden in this region, we used CDC HIV surveillance data to examine characteristics of individuals diagnosed with HIV in the targeted states (2011), 5-year HIV and AIDS survival, and deaths among persons living with HIV (2010). We used multivariable analyses to explore the influence of residing in the targeted states at diagnosis on deaths among persons living with HIV after adjustment for demographics and transmission risk. In 2011, the targeted states had a higher HIV diagnosis rate (24.5/100,000 population) than the US overall (18.0/100,000) and higher proportions than other regions of individuals diagnosed with HIV who were black, female, younger, and living in suburban and rural areas. Furthermore, the targeted states had lower HIV and AIDS survival proportions (0.85, 0.73, respectively) than the US overall (0.86, 0.77, respectively) and the highest death rate among persons living with HIV of any US region. Regional differences in demographics and transmission risk did not explain the higher death rate among persons living with HIV in the targeted states indicating that other factors contribute to this disparity. Differences in characteristics and outcomes of individuals with HIV in the targeted states are critical to consider when creating strategies to address HIV in the region, as are other factors identified in previous research to be prominent in the region including poverty and stigma.Entities:
Mesh:
Year: 2015 PMID: 25524210 PMCID: PMC4490182 DOI: 10.1007/s10900-014-9979-7
Source DB: PubMed Journal: J Community Health ISSN: 0094-5145
Characteristics of individuals diagnosed with HIV in selected states in the Southern United Statesa and US regions, 2011
| Targeted States | United States | South | South non-targeted states | Northeast | Midwest | West | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| % | Rate | % | Rate | % | Rate | % | Rate | % | Rate | % | Rate | % | Rate | |
| Sex | ||||||||||||||
| Male | 76.7 | 38.7 | 79.1 | 29.2 | 76.5 | 36.9 | 75.7 | 31.5 | 75.9 | 31.9 | 80.8 | 17.9 | 88.3 | 25.5 |
| Female | 23.3 | 11.1 | 20.9 | 7.4 | 23.5 | 10.7 | 24.3 | 9.6 | 24.1 | 9.4 | 19.2 | 4.1 | 11.7 | 3.3 |
| Race/ethnicity | ||||||||||||||
| Black/African American | 56.5 | 72.9 | 46.6 | 70 | 58 | 73.7 | 63.6 | 76.5 | 43.9 | 81.8 | 48.6 | 53 | 18.3 | 57.8 |
| Hispanic/Latino | 17.6 | 24.5 | 20.9 | 24.9 | 15.7 | 24.8 | 8.3 | 27.2 | 26 | 44.1 | 10.9 | 19 | 35.9 | 19.5 |
| White | 23 | 9.5 | 28 | 7.7 | 23.3 | 8.8 | 24.3 | 7 | 25.6 | 7.4 | 35.6 | 4.8 | 37.4 | 9.7 |
| Multiple races | 1.7 | 41.1 | 2 | 25.2 | 1.8 | 35.2 | 2.1 | 24.7 | 2.2 | 41.5 | 3 | 28 | 1.5 | 9.3 |
| Other | 1.2 | 9.1 | 2.6 | 8.1 | 1.3 | 8.3 | 1.6 | 6.7 | 2.3 | 7.7 | 1.9 | 6.5 | 6.8 | 8.5 |
| Age at diagnosis | ||||||||||||||
| 13–24 | 23.3 | 28.2 | 21.4 | 19.2 | 23 | 26.9 | 22.2 | 22.8 | 18.8 | 19.6 | 25.4 | 13.7 | 17.2 | 11.9 |
| 25–34 | 27.1 | 40.9 | 27.9 | 31.1 | 26.9 | 38.9 | 26.2 | 32.7 | 27.1 | 35.9 | 28.2 | 19.5 | 31 | 25.7 |
| 35–44 | 21.3 | 32.6 | 22.4 | 25.7 | 21.2 | 31.3 | 21.1 | 27.3 | 23.3 | 30.5 | 21.6 | 15.5 | 24.8 | 22 |
| 45–54 | 19 | 27.4 | 19.2 | 20 | 19.3 | 26.5 | 20.5 | 23.7 | 20.3 | 22.8 | 17.5 | 10.8 | 18.8 | 16.1 |
| 55+ | 9.4 | 7.6 | 9.2 | 5.4 | 9.5 | 7.3 | 10 | 6.5 | 10.5 | 6.7 | 7.2 | 2.5 | 8.1 | 4 |
|
| ||||||||||||||
| Male | ||||||||||||||
| Male-to-male sexual contact | 78.1 | NA | 79 | NA | 77.6 | NA | 75.8 | NA | 72.2 | NA | 83.9 | NA | 85.5 | NA |
| Injection drug use | 4.3 | NA | 5.6 | NA | 4.6 | NA | 5.6 | NA | 9.8 | NA | 4.2 | NA | 4.6 | NA |
| Male-to-male sexual contact and injection drug use | 3 | NA | 3.6 | NA | 3 | NA | 3.1 | NA | 2.9 | NA | 3.7 | NA | 5.7 | NA |
| Heterosexual contact | 14.5 | NA | 11.7 | NA | 14.7 | NA | 15.3 | NA | 15 | NA | 7.9 | NA | 4.2 | NA |
| Otherb | 0.1 | NA | 0.1 | NA | 0.1 | NA | 0.2 | NA | 0 | NA | 0.2 | NA | 0.1 | NA |
| Female | ||||||||||||||
| Injection drug use | 11.5 | NA | 14.1 | NA | 11.6 | NA | 12.1 | NA | 16.9 | NA | 14.4 | NA | 20.5 | NA |
| Heterosexual contact | 88.3 | NA | 85.7 | NA | 88.2 | NA | 87.8 | NA | 83.1 | NA | 85.3 | NA | 79 | NA |
| Otherb | 0.1 | NA | 0.2 | NA | 0.1 | NA | 0.1 | NA | 0.1 | NA | 0.3 | NA | 0.5 | NA |
| Residence at diagnosis | ||||||||||||||
| Urban (MSAs with population ≥500,000) | 72.2 | 29.6 | 81.7 | 22.5 | 74.7 | 29.5 | 83.7 | 29.4 | 92.5 | 23.4 | 80.3 | 15.7 | 89.2 | 17.4 |
| Suburban (metropolitan areas with population 50,000–499,999) | 16.5 | 18.6 | 11.1 | 11.1 | 14.7 | 16.5 | 7.9 | 8.8 | 4.8 | 9.4 | 12.5 | 6.2 | 7.9 | 6.8 |
| Rural (nonmetropolitan areas) | 10.7 | 14.4 | 6.6 | 7.3 | 10 | 11.9 | 7.2 | 6.1 | 2.2 | 4.5 | 6.8 | 3.2 | 2.5 | 3.6 |
| Unknown | 0.5 | – | 0.5 | – | 0.6 | – | 1.1 | – | 0.5 | – | 0.4 | – | 0.4 | – |
| Stage of disease at diagnosis | ||||||||||||||
| Stage 3 (AIDS)c | 28.5 | NA | 28.7 | NA | 28.3 | NA | 27.8 | NA | 29.2 | NA | 28.4 | NA | 29.2 | NA |
| Stage 1 or 2 or unknown | 71.5 | NA | 71.3 | NA | 71.7 | NA | 72.2 | NA | 70.8 | NA | 71.6 | NA | 70.8 | NA |
| Total | 100 | 24.5 | 100 | 18 | 100 | 23.5 | 100 | 20.2 | 100 | 20.2 | 100 | 10.8 | 100 | 14.3 |
aIncludes Alabama, Florida, Georgia, Louisiana, Mississippi, North Carolina, South Carolina, Tennessee, Texas
bIncludes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified
cAIDS within 3 months of HIV diagnosis
HIV prevalence in selected Southern Statesa and other United States Regions, year-end 2010
| Targeted states | United States | South | Southern non-target | Northeast | Midwest | West | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| % | Rate | % | Rate | % | Rate | % | Rate | % | Rate | % | Rate | % | Rate | |
| Sex | ||||||||||||||
| Male | 72.3 | 595.9 | 75.1 | 521 | 72 | 575.7 | 71 | 514 | 69.5 | 717.6 | 78.9 | 294.8 | 87.4 | 493.2 |
| Female | 27.7 | 215.4 | 24.9 | 164.4 | 28.0 | 211.1 | 29 | 198.2 | 30.5 | 291.7 | 21.1 | 75.0 | 12.6 | 70.0 |
| Race/ethnicity | ||||||||||||||
| Black/African American | 54.2 | 1,144.9 | 43.6 | 1,231.6 | 56.2 | 1,184.9 | 63.2 | 1,321.8 | 42.9 | 1,966.7 | 44.2 | 815.5 | 16.2 | 1,001.0 |
| Hispanic/Latino | 14.6 | 336.9 | 19.0 | 433.0 | 12.6 | 336.5 | 5.7 | 332.4 | 27.1 | 1,148.4 | 9.5 | 288.9 | 27.7 | 297.0 |
| White | 29.0 | 194.7 | 33.8 | 173.1 | 28.8 | 179.3 | 28.1 | 139.9 | 26.0 | 183 | 42.5 | 97.1 | 50.6 | 254.1 |
| Multiple races | 1.5 | 622.1 | 1.9 | 474.2 | 1.6 | 536.6 | 1.9 | 386.5 | 2.9 | 1,334.5 | 2.3 | 367.5 | 1.2 | 152.0 |
| Other | 0.7 | 85.4 | 1.6 | 97.6 | 0.8 | 85.0 | 1.2 | 84.3 | 1.2 | 102.3 | 1.5 | 85.0 | 4.3 | 105.1 |
| Age at end of year | ||||||||||||||
| 13–24 | 5.2 | 101.3 | 4.5 | 74.4 | 5.1 | 97.8 | 4.9 | 86.8 | 4.2 | 106.5 | 5.4 | 48.6 | 2.9 | 38.1 |
| 25–34 | 16.5 | 407.5 | 14 | 295.1 | 16.1 | 385.9 | 14.6 | 319.8 | 10.9 | 359.9 | 15.6 | 183 | 12.8 | 208.2 |
| 35–44 | 28.1 | 692.0 | 26.7 | 565.1 | 27.8 | 665.9 | 26.4 | 584.8 | 24.3 | 765.7 | 28.1 | 332.4 | 26.8 | 458.2 |
| 45–54 | 33.6 | 780.5 | 35.5 | 685 | 34 | 759.6 | 35.3 | 697.9 | 37.5 | 1,026.9 | 34.2 | 348.5 | 36.9 | 607.1 |
| 55+ | 16.6 | 222.3 | 19.3 | 216.7 | 17.1 | 220.8 | 18.7 | 216.2 | 23.0 | 363.1 | 16.7 | 98.5 | 20.6 | 202.7 |
|
| ||||||||||||||
| Male | ||||||||||||||
| Male-to-male sexual contact | 68.4 | NA | 67.7 | NA | 67.2 | NA | 63.0 | NA | 55.1 | NA | 75.2 | NA | 78.4 | NA |
| Injection drug use | 9.3 | NA | 13.0 | NA | 10.6 | NA | 15.5 | NA | 25.0 | NA | 8.6 | NA | 6.4 | NA |
| Male-to-male sexual contact and injection drug use | 7.0 | NA | 7.5 | NA | 7.0 | NA | 6.9 | NA | 5.7 | NA | 7.7 | NA | 10.5 | NA |
| Heterosexual contact | 14.5 | NA | 10.8 | NA | 14.3 | NA | 13.6 | NA | 12.6 | NA | 7.4 | NA | 4.0 | NA |
| Otherb | 0.9 | NA | 1.1 | NA | 0.9 | NA | 1.1 | NA | 1.6 | NA | 1.1 | NA | 0.6 | NA |
| Female | ||||||||||||||
| Injection drug use | 18.0 | NA | 24.9 | NA | 19.7 | NA | 25.5 | NA | 32.6 | NA | 21.9 | NA | 26.8 | NA |
| Heterosexual contact | 79.8 | NA | 72.3 | NA | 78 | NA | 72.2 | NA | 63.9 | NA | 75.5 | NA | 69.6 | NA |
| Otherb | 2.2 | NA | 2.8 | NA | 2.2 | NA | 2.2 | NA | 3.5 | NA | 2.6 | NA | 3.6 | NA |
| Residence at diagnosis | ||||||||||||||
| Urban (MSAs with population ≥500,000) | 73.6 | 493.9 | 82.8 | 428.8 | 75.6 | 496.7 | 82.6 | 505.7 | 91.4 | 568.1 | 79.1 | 261.1 | 89.2 | 340.0 |
| Suburban (metropolitan areas with population 50,000–499,999) | 14.9 | 271.3 | 10.0 | 185.6 | 13.5 | 248.2 | 8.6 | 164.4 | 4.9 | 236.7 | 13.0 | 109.2 | 7.5 | 126.9 |
| Rural (nonmetropolitan areas) | 10.6 | 231.6 | 6.2 | 127.7 | 9.8 | 192.2 | 6.9 | 101.0 | 2.7 | 137.7 | 6.8 | 53.5 | 2.7 | 75.9 |
| Unknown | 0.9 | – | 1.0 | – | 1.1 | – | 1.8 | – | 1.0 | – | 1.1 | – | 0.6 | – |
| Total | 100 | 400.3 | 100 | 338.3 | 100 | 388.2 | 100 | 351.5 | 100 | 496.6 | 100 | 182.3 | 100 | 279.8 |
aIncludes Alabama, Florida, Georgia, Louisiana, Mississippi, North Carolina, South Carolina, Tennessee, Texas
bIncludes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified
Survival for more than 60 months after a diagnosis of AIDS or a diagnosis of HIV infection, adults and adolescents (aged 13 years or over) diagnosed in 2003–2004 in selected Southern Statesa and other United States Regions
| Proportion survived | ||
|---|---|---|
| AIDS survival | HIV survival | |
| United Statesb | 0.77 | 0.86 |
| Targeted statesb | 0.73 | 0.85 |
| State of residence | ||
| Alabama | 0.69 | 0.86 |
| Florida | 0.72 | 0.85 |
| Georgia | 0.75 | 0.86 |
| Louisiana | 0.67 | 0.81 |
| Mississippi | 0.68 | 0.83 |
| North Carolina | 0.74 | 0.85 |
| South Carolina | 0.73 | 0.84 |
| Tennessee | 0.72 | 0.85 |
| Texas | 0.76 | 0.87 |
|
| ||
| Sex | ||
| Male | 0.74 | 0.85 |
| Female | 0.71 | 0.85 |
| Race/ethnicity | ||
| Black/African American | 0.70 | 0.84 |
| Hispanic/Latino | 0.78 | 0.87 |
| White | 0.76 | 0.87 |
| Multiple races | 0.73 | 0.84 |
| Other | 0.78 | 0.89 |
| Age at diagnosis | ||
| 13–24 | 0.83 | 0.95 |
| 25–34 | 0.79 | 0.91 |
| 35–44 | 0.75 | 0.86 |
| 45–54 | 0.67 | 0.78 |
| 55+ | 0.52 | 0.61 |
|
| ||
| Male adult or adolescent | ||
| Male-to-male sexual contact | 0.79 | 0.90 |
| Injection drug use | 0.66 | 0.80 |
| Male-to-male sexual contact and injection drug use | 0.75 | 0.88 |
| Heterosexual contact | 0.72 | 0.83 |
| Otherc | 0.64 | 0.76 |
| Female adult or adolescent | ||
| Injection drug use | 0.63 | 0.80 |
| Heterosexual contact | 0.75 | 0.88 |
| Otherc | 0.66 | 0.82 |
| Residence at diagnosis | ||
| Urban (MSAs with population ≥500,000) | 0.73 | 0.86 |
| Suburban (metropolitan areas with population 50,000–499,999) | 0.71 | 0.84 |
| Rural (nonmetropolitan areas) | 0.71 | 0.82 |
| Unknown | 0.82 | 0.93 |
aIncludes Alabama, Florida, Georgia, Louisiana, Mississippi, North Carolina, South Carolina, Tennessee, Texas
bExcludes cases diagnosed prior to the earlier date of HIV code-based and name-based reporting dates. Therefore, (1) ‘United States’ excludes PA, (2) ‘Targeted states’ includes all the nine targeted-states (GA has only 2004 data), and (3) ‘Other states’ includes the other states (40 states + DC excluding PA) of (1)
cIncludes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified
Death rate among persons living with HIV, adjusted and adjusted by United States region and by specific characteristics within selected Southern Statesa, 2010
| Unadjusted rate | Adjusted rated | Rate ratio (CI) | |
|---|---|---|---|
| Rate of deaths 2010 (among 1,000 PLWH and new diagnoses during 2010)c | Rate of deaths 2010 (among 1,000 PLWH and new diagnoses during 2010)c | ||
| United States | 24.0 | ||
| Region of residence | |||
| Northeast | 24.7 | 22.3 | 0.77 (0.74,0.80) |
| Midwest | 20.7 | 22.5 | 0.77 (0.74,0.81) |
| South | 26.7 | 28.0 | |
| Targeted statesa | 27.3 | 29.0 | Reference |
| South non-targeted states | 24.6 | 24.0 | 0.83 (0.79,0.87) |
| West | 18.8 | 21.2 | 0.73 (0.70,0.76) |
| State of residence | |||
| Alabama | 30.7 | ||
| Florida | 29.1 | ||
| Georgia | 28.4 | ||
| Louisiana | 34.5 | ||
| Mississippi | 28.6 | ||
| North Carolina | 25.6 | ||
| South Carolina | 29.6 | ||
| Tennessee | 25.0 | ||
| Texas | 22.2 | ||
|
| |||
| Sex | |||
| Male | 26.9 | ||
| Female | 28.2 | ||
| Race/ethnicity | |||
| Black/African American | 30.0 | ||
| Hispanic/Latino | 19.8 | ||
| White | 25.5 | ||
| Multiple races | 41.1 | ||
| Other | 12.4 | ||
| Age category | |||
| 13–24 | 7.5 | ||
| 25–34 | 13.5 | ||
| 35–44 | 20.3 | ||
| 45–54 | 31.2 | ||
| 55+ | 56.9 | ||
|
| |||
| Male adult or adolescent | |||
| Male-to-male sexual contact | 21.5 | ||
| Injection drug use | 45.1 | ||
| Male-to-male sexual contact and injection drug use | 36.1 | ||
| Heterosexual contact | 36.0 | ||
| Otherb | 26.3 | ||
| Female adult or adolescent | |||
| Injection drug use | 39.0 | ||
| Heterosexual contact | 26.0 | ||
| Otherb | 18.0 | ||
| Residence at diagnosis | |||
| Urban (MSAs with population ≥500,000) | 25.6 | ||
| Suburban (metropolitan areas with population 50,000–499,999) | 32.5 | ||
| Rural (nonmetropolitan areas) | 31.8 | ||
| Unknown | 22.4 | ||
aIncludes Alabama, Florida, Georgia, Louisiana, Mississippi, North Carolina, South Carolina, Tennessee, and Texas
bIncludes hemophilia, blood transfusion, perinatal exposure, and risk factor not reported or not identified
cRates are per 1,000 persons living with diagnosed HIV infection (PLWH), denominator was calculated as (No. of PLWH at the end of 2009 + new diagnoses during 2010)
dAdjusted for age, race/ethnicity, sex, transmission category, residence at diagnosis